candidiasis

Showing 1 posts of 1 posts found.

Novartis drops two drug candidates, takes $600 million hit

October 6, 2010
Research and Development Human Genome Sciences, Novartis, candidiasis, hepatitis

Novartis will incur a charge of nearly $600 million after it halted development of investigational drugs for hepatitis C and …

Latest content